Rose Geoffrey Beran sold $18K of LUNG

Rose Geoffrey Beran (Chief Commercial Officer) sold 7,879 shares of Pulmonx Corp (LUNG) at $2.26 across 4 trades on 2026-09-01.

Original reporting
SEC EDGAR · Rose Geoffrey Beran
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LUNG
Neutral
high confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

The sale is routine and unlikely to affect price materially.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases or FDA decisions could outweigh the impact of this small sale.

Relevance 3/10Novelty 3/10Timing: same‑day filing

Background

SEC Form 4 disclosures provide the first public record of insider trades.

Company-level read

Ticker impact

$LUNGNeutralHigh confidence
Context

Chief Commercial Officer sold 7,879 shares of Pulmonx (LUNG) for $17,806.54 in a Form 4 filing.

Expected impact

Minimal downward pressure, likely within normal trading noise.

Evidence & confidence

Sale represents less than 2% of the insider's post‑transaction holdings and the amount is small ($18K).

Market effects

None; Pulmonx operates in a niche medical device segment with limited peer impact.

No regional effect; the transaction is company‑specific.

Low; the filing does not affect broader market sentiment.

Counterpoint

If the sale signals insider concern, a short‑term dip could be exploited.

Key entities

  • Pulmonx Corp

    Medical device company listed on NASDAQ under LUNG.

  • Rose Geoffrey Beran

    Chief Commercial Officer of Pulmonx.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.